A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

NCT05132413 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

561

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer

Interventions

DRUG: SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
DRUG: Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
DRUG: Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.